http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7879870-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2d5e65f79abb31171578e2f23712020 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d282a8fd47ff43186bf2b676de65d2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38d8c5b4dad08e446fc516dc41a1f0d7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate | 2007-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a58ab52755eccd8c137a23a2fcae8814 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5b638be42d43b91d1f204e7c0b03871 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a6ab145e9d7d5fea327220daec1ea39 |
| publicationDate | 2011-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7879870-B2 |
| titleOfInvention | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
| abstract | Methods for the treatment of inflammatory and ulcerative diseases of the bowel (e.g., Crohn's disease and ulcerative colitis) with a therapeutically effective dose less than 50 mg. of opioid antagonists (e.g., naltrexone, nalmefene or naloxone) are disclosed. An embodiment of the invention includes a method of pharmaceutical treatment comprising orally administering to a human subject having Crohn's disease or ulcerative colitis a therapeutic pharmaceutical composition once per day in the evening or at bedtime, wherein the pharmaceutical composition comprises form about 3 mg to about 4.5 mg of naltrexone, nalmefene, naloxone, or a hydrochloride salt thereof in an immediate release solid dosage formulation. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021005501-A1 |
| priorityDate | 2006-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 335.